⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNGX News
Soligenix, Inc. Common Stock
Form 8-K
sec.gov
SNGX
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
prnewswire.com
SNGX
Form 8-K
sec.gov
SNGX
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
prnewswire.com
SNGX
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
SNGX
IPHA
BMY
NKTX
AZN
MRK
TAK
NVS
GMAB
ABBV
BIIB
CRSP
INCY
ALKS
PFE
REGN
GILD
AMGN
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
prnewswire.com
SNGX
Form 8-K
sec.gov
SNGX
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
prnewswire.com
SNGX
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
accessnewswire.com
BKYI
AIDX
SOPA
SNGX
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
prnewswire.com
SNGX